Jazz Pharmaceuticals JAZZ Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Accumulated Amortization at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's finite-lived intangible assets, accumulated amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
- Jazz Pharmaceuticals (JAZZ) reported finite-lived intangible assets, accumulated amortization of $3.89B in Q1 2026.
- How has Jazz Pharmaceuticals's finite-lived intangible assets, accumulated amortization changed year-over-year?
- Jazz Pharmaceuticals's finite-lived intangible assets, accumulated amortization increased by 22.2% year-over-year, from $3.18B to $3.89B.
- What is the long-term trend for Jazz Pharmaceuticals's finite-lived intangible assets, accumulated amortization?
- Over 5 years (2020 to 2025), Jazz Pharmaceuticals's finite-lived intangible assets, accumulated amortization has grown at a 25.8% compound annual growth rate (CAGR), from $1.2B to $3.78B.